<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03159208</url>
  </required_header>
  <id_info>
    <org_study_id>16-0998</org_study_id>
    <secondary_id>R01NR016459</secondary_id>
    <nct_id>NCT03159208</nct_id>
  </id_info>
  <brief_title>Prediction of Functional Outcomes From Chronic Critical Illness</brief_title>
  <official_title>Prediction of Functional Outcomes From Chronic Critical Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Nursing Research (NINR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to establish clinical determinants of poor cognitive and physical
      functional outcome of CCI patients so that the investigators may develop and validate a
      multi-dimensional clinical prediction model to more effectively inform decision making
      earlier in the course of the ICU care. The investigators hypothesize that multiple premorbid
      and acute factors measured early in the course of CCI will have strong independent
      associations with functional recovery. The investigators further hypothesize that social and
      economic factors are associated with long-term functional outcomes independent of the acute
      clinical problems.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A substantial number of critically ill patients experience persistent organ failure leading
      to chronic critical illness (CCI). The majority of these patients die within a year, and many
      survivors must cope with long-term physical and cognitive limitations that are often severe.
      Survival with severe physical and cognitive dysfunction is a significant clinical, emotional,
      and economic burden in this population, but little is known about which patients are at
      highest risk for physical and cognitive dysfunction. Moreover, although long-term mortality
      in CCI can be reliably estimated with a validated mortality prediction model, there is
      currently no validated method to predict long-term functional disability for purposes of
      shared decision-making and resource planning. In order to address these gaps in knowledge,
      the investigators will conduct a multi-center prospective cohort study that measures clinical
      and premorbid risk factors for long-term physical and cognitive dysfunction in CCI. Using
      these risk factors, the investigators will construct a multi-outcome prognostic model for
      survival with severe physical or cognitive dysfunction to facilitate shared decision-making
      and resource planning. Additionally, the investigators will identify independent social and
      economic variables that are risk factors for long-term survival and functional disability.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 17, 2017</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients who Survive with Severe Physical Disability</measure>
    <time_frame>12 months</time_frame>
    <description>Severe Physical Disability defined by requiring assistance with 4 of 6 or more Activities of Daily Living (ADLs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Patients who Survive with Severe Cognitive Disability</measure>
    <time_frame>12 months</time_frame>
    <description>Severe Cognitive Disability defined by the Informant Questionnaire on Cognitive Delay (IQCODE) average score of greater than 3.44 (range 0-5, 5 being worse) and, when available, the Telephone Montreal Cognitive Assessment (T-MoCA) score of less than 17 (Range 0-22, 0 being worse). Severity of Cognitive Delay will be confirmed with a Functional Activities Questionnaire (FAQ) score of greater than 8 (Range 0-30, 30 being worst).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Patients who Survive with Severe Physical and Cognitive Disability</measure>
    <time_frame>12 months</time_frame>
    <description>Severe Physical Disability defined by requiring assistance with 4 of 6 or more Activities of Daily Living (ADLs). Severe Cognitive Disability defined by the Informant Questionnaire on Cognitive Delay (IQCODE) average score of greater than 3.44 (range 0-5, 5 being worse) and, when available, the Telephone Montreal Cognitive Assessment (T-MoCA) score of less than 17 (Range 0-22, 0 being worse). Severity of Cognitive Delay will be confirmed with a Functional Activities Questionnaire (FAQ) score of greater than 8 (Range 0-30, 30 being worst).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Patients who Survive with No Severe Functional Disability</measure>
    <time_frame>12 months</time_frame>
    <description>No severe physical disability is indicated by requiring assistance with 3 or fewer Activities of Daily Living (ADLs). No Severe Cognitive Disability is defined by the Informant Questionnaire on Cognitive Delay (IQCODE) average score of less than 3.44 (range 0-5) and, when available, the Telephone Montreal Cognitive Assessment (T-MoCA) score of greater than 17 (Range 0-22).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who die within one year</measure>
    <time_frame>12 months</time_frame>
    <description>Confirmed dead at 1-year follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients who Survive with Severe Physical Disability</measure>
    <time_frame>6 months</time_frame>
    <description>Severe Physical Disability defined by requiring assistance with 4 of 6 or more Activities of Daily Living (ADLs).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients who Survive with Severe Cognitive Disability</measure>
    <time_frame>6 months</time_frame>
    <description>Severe Cognitive Disability defined by the Informant Questionnaire on Cognitive Delay (IQCODE) average score of greater than 3.44 (range 0-5, 5 being worse) and, when available, the Telephone Montreal Cognitive Assessment (T-MoCA) score of less than 17 (Range 0-22, 0 being worse). Severity of Cognitive Delay will be confirmed with a Functional Activities Questionnaire (FAQ) score of greater than 8 (Range 0-30, 30 being worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients who Survive with Severe Physical and Cognitive Disability</measure>
    <time_frame>6 months</time_frame>
    <description>Severe Physical Disability defined by requiring assistance with 4 of 6 or more Activities of Daily Living (ADLs). Severe Cognitive Disability defined by the Informant Questionnaire on Cognitive Delay (IQCODE) average score of greater than 3.44 (range 0-5, 5 being worse) and, when available, the Telephone Montreal Cognitive Assessment (T-MoCA) score of less than 17 (Range 0-22, 0 being worse). Severity of Cognitive Delay will be confirmed with a Functional Activities Questionnaire (FAQ) score of greater than 8 (Range 0-30, 30 being worst).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients who Survive with No Severe Functional Disability</measure>
    <time_frame>6 months</time_frame>
    <description>No severe physical disability is indicated by requiring assistance with 3 or fewer Activities of Daily Living (ADLs). No Severe Cognitive Disability is defined by the Informant Questionnaire on Cognitive Delay (IQCODE) average score of less than 3.44 (range 0-5) and, when available, the Telephone Montreal Cognitive Assessment (T-MoCA) score of greater than 17 (Range 0-22).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who die within 6 months.</measure>
    <time_frame>6 months</time_frame>
    <description>Confirmed dead at 6 month follow up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life Score: NeuroQOL</measure>
    <time_frame>6 and 12 months.</time_frame>
    <description>Quality of Life with cognitive ability is measured by Quality of Life in Neurological Disorders (NeuroQOL) with 8-items Scores range from 8-20. The higher score indicates better health state perceived by participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Quality of Life Score: EQ-5D</measure>
    <time_frame>6 and 12 months.</time_frame>
    <description>Quality of Life is measured by EQ-5D Questionnaire via 5 items: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The score ranges from -0.594 to 1.000 in the US. The higher score indicates a better health state perceived by the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Quality of Life Score: EQ-5D</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Quality of Life is measured by EQ-5D Questionnaire via 5 items: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The score ranges from -0.594 to 1.000 in the US. The higher score indicates a better health state perceived by the participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Burden Score: BSFC</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Caregiver burden is measured by the Burden Scale for Family Caregivers (BSFCs) with 10-items and are rated on a scale from 0 (strongly disagree) to 3 (strongly agree). The score ranges from 0 to 30 points. The higher scores indicate greater caregiver burden.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver Anxiety and Depression Score: HADS</measure>
    <time_frame>12 months</time_frame>
    <description>Caregiver Depression and Anxiety is measured by the Hospital Anxiety and Depression Scale (HADS) with 14-items. Scores for each subscale (anxiety and depression) range from 0 to 21. Scores for the entire scale range from 0 to 42. The higher scores indicating more distress.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Caregiver PTSD Score: IES-R</measure>
    <time_frame>12 months</time_frame>
    <description>Caregiver PTSD symptoms is measured by Impact of Events Scale-Revised (IES-R) with 22-items. Scores for each subscale (avoidance, intrusion, hyperarousal) range from 0-12. Scores for the entire scale range from 0-88. The higher scores are associated with clinical symptoms of PTSD.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Chronic Critical Illness</condition>
  <condition>Prolonged Mechanical Ventilation</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole Blood, Serum, Urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients at risk for chronic critical illness after prolonged mechanical ventilation for
        acute illness or injury.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Patients in enrolling ICU

          2. Expected to require 7 days of mechanical ventilation uninterrupted for 72 hours for
             acute illness.

          3. Adults &gt;/= 18yo of age.

        Exclusion Criteria

          1. Patients with respiratory failure due to neuromuscular disease

          2. Patients with respiratory failure due to severe burn

          3. Patients requiring chronic mechanical ventilation at home

          4. Patients receiving mechanical ventilation at an outside hospital &gt;7 days

          5. Expected death prior to day 8 of mechanical ventilation therapies in 24 hrs.

          6. Prisoners

          7. No family member or surrogate available

          8. Patient not proficient in English

          9. Unwilling or unable to provide written informed consent (patient or when indicated, by
             surrogate)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shannon Carson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Summer Choudhury, MPH</last_name>
    <phone>919-966-2531</phone>
    <email>summer_choudhury@med.unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Denver Health and Hospital Authority</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivor Douglas, MD</last_name>
      <phone>303-602-5012</phone>
      <email>idouglas@dhha.org</email>
    </contact>
    <investigator>
      <last_name>Ivor Douglas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina-Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Summer Choudhury, MPH</last_name>
      <phone>919-966-2531</phone>
      <email>summer_choudhury@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Shannon Carson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Cox, MD</last_name>
      <phone>919-681-7232</phone>
      <email>christopher.cox@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Cox, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doug White, MD</last_name>
      <phone>412-864-3757</phone>
      <email>whitedb@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Doug White, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terri Hough, MD</last_name>
      <phone>206-744-4523</phone>
      <email>cterrlee@uw.edu</email>
    </contact>
    <investigator>
      <last_name>Terri Hough, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Hough CL, Caldwell ES, Cox CE, Douglas IS, Kahn JM, White DB, Seeley EJ, Bangdiwala SI, Rubenfeld GD, Angus DC, Carson SS; ProVent Investigators and the National Heart Lung and Blood Instituteâ€™s Acute Respiratory Distress Syndrome Network. Development and Validation of a Mortality Prediction Model for Patients Receiving 14 Days of Mechanical Ventilation. Crit Care Med. 2015 Nov;43(11):2339-45. doi: 10.1097/CCM.0000000000001205.</citation>
    <PMID>26247337</PMID>
  </reference>
  <reference>
    <citation>Kahn JM, Le T, Angus DC, Cox CE, Hough CL, White DB, Yende S, Carson SS; ProVent Study Group Investigators. The epidemiology of chronic critical illness in the United States*. Crit Care Med. 2015 Feb;43(2):282-7. doi: 10.1097/CCM.0000000000000710.</citation>
    <PMID>25377018</PMID>
  </reference>
  <reference>
    <citation>Nelson JE, Cox CE, Hope AA, Carson SS. Chronic critical illness. Am J Respir Crit Care Med. 2010 Aug 15;182(4):446-54. doi: 10.1164/rccm.201002-0210CI. Epub 2010 May 6. Review.</citation>
    <PMID>20448093</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2017</study_first_submitted>
  <study_first_submitted_qc>May 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prognosis</keyword>
  <keyword>Critical Illness</keyword>
  <keyword>Ventilation, Mechanical</keyword>
  <keyword>Disease Attributes</keyword>
  <keyword>Socioeconomic Factors</keyword>
  <keyword>Activities of Daily LIving</keyword>
  <keyword>Cognition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A deidentified dataset will be available to investigators one year following primary publication of the study. Data can be obtained upon application to primary investigators.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

